Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
2.61 USD
−190.60 M USD
1.04 B USD
51.05 M
About Emergent BioSolutions Inc.
Sector
Industry
CEO
Joseph C. Papa
Website
Headquarters
Gaithersburg
Founded
1998
ISIN
US29089Q1058
FIGI
BBG000GW06J7
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
EBS5025997
Emergent BioSolutions Inc. 3.875% 15-AUG-2028Yield to maturity
11.94%
Maturity date
Aug 15, 2028
EBS5025998
Emergent BioSolutions Inc. 3.875% 15-AUG-2028Yield to maturity
—
Maturity date
Aug 15, 2028
See all EBS bonds
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BOATS exchange Emergent BioSolutions Inc. stocks are traded under the ticker EBS.
We've gathered analysts' opinions on Emergent BioSolutions Inc. future price: according to them, EBS price has a max estimate of 15.00 USD and a min estimate of 12.00 USD. Watch EBS chart and read a more detailed Emergent BioSolutions Inc. stock forecast: see what analysts think of Emergent BioSolutions Inc. and suggest that you do with its stocks.
Yes, you can track Emergent BioSolutions Inc. financials in yearly and quarterly reports right on TradingView.
Emergent BioSolutions Inc. is going to release the next earnings report on Nov 5, 2025. Keep track of upcoming events with our Earnings Calendar.
EBS earnings for the last quarter are 0.16 USD per share, whereas the estimation was −0.41 USD resulting in a 138.71% surprise. The estimated earnings for the next quarter are 0.05 USD per share. See more details about Emergent BioSolutions Inc. earnings.
Emergent BioSolutions Inc. revenue for the last quarter amounts to 140.90 M USD, despite the estimated figure of 146.37 M USD. In the next quarter, revenue is expected to reach 203.67 M USD.
EBS net income for the last quarter is −12.00 M USD, while the quarter before that showed 68.00 M USD of net income which accounts for −117.65% change. Track more Emergent BioSolutions Inc. financial stats to get the full picture.
No, EBS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 25, 2025, the company has 900 employees. See our rating of the largest employees — is Emergent BioSolutions Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Emergent BioSolutions Inc. EBITDA is 213.10 M USD, and current EBITDA margin is 5.14%. See more stats in Emergent BioSolutions Inc. financial statements.
Like other stocks, EBS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Emergent BioSolutions Inc. stock right from TradingView charts — choose your broker and connect to your account.